한글목차

바이러스성 결막염 치료제 시장은 2025년에는 3억 7,500만 달러로 추정되며, 2032년에는 5억 3,120만 달러에 달할 것으로 예측되며, 2025-2032년까지 CAGR 5.1%로 성장할 것으로 예측됩니다.

바이러스성 결막염은 아데노바이러스, 헤르페스 바이러스 등 다양한 바이러스에 의해 발생하는 급성 결막염입니다. 바이러스성 결막염은 감염성 결막염의 대부분을 차지하며, 전체 결막염의 75%를 차지합니다. 바이러스성 결막염의 특징으로는 충혈, 혈관 충혈, 눈곱, 통증, 충혈 등을 들 수 있습니다. 아데노바이러스군에 의한 바이러스성 결막염은 유행성각결막염(EKC)이라고 합니다. 아데노바이러스 그룹에는 다양한 혈청형이 있으며, 인두결막열과 비특이적 여포성 결막염을 유발할 수 있으며, American Academy of Ophthalmology: 2018에 발표된 논문에 따르면 아데노바이러스성 결막염은 성인 인구에서 가장 흔한 안구 감염 입니다. 아데노바이러스 결막염은 감염을 일으키는 바이러스가 조리대나 유사한 표면에서 몇 주 동안 생존할 수 있기 때문에 전염성이 매우 강합니다.

시장 역학

개발업체들은 아데노바이러스성 결막염에 대한 보다 효율적인 치료법을 개발하기 위해 임상시험을 진행하고 있으며, 이는 예측 기간 동안 시장 성장에 기여할 수 있습니다. 예를 들어, 2017년 다케다제약의 자회사 Shire Plc는 아데노바이러스성 결막염을 앓고 있는 성인과 소아를 대상으로 SHP640의 안전성과 유효성을 검증하기 위한 임상시험을 시작했습니다.

시장 진입 기업들은 신제품 출시에 주력하고 있으며, 세계 시장에서의 입지를 강화할 것으로 예상됩니다. 예를 들어, 2018년 Abbvie Inc.의 자회사인 Allergan plc.는 새로운 일반의약품(OTC) 인공눈물 제제 '리프레쉬 리페어 윤활 점안액'을 출시했습니다. 카복시메틸셀룰로오스(CMC), 히알루론산(HA, 비활성 성분), 삼투압 보호제가 함유되어 있어 안구건조증과 같은 결막염 증상의 유해성으로부터 눈을 보호합니다.

시장 진입 기업들은 유통을 강화하기 위해 다른 기업들과 파트너십을 맺어 세계 입지를 확장하고 있으며, 이는 바이러스성 결막염 치료제 시장의 성장을 촉진할 것으로 예상됩니다. 예를 들어, 2018년 Mundipharma Deutschland GmbH & Co.KG(제약회사)는 NTC(이탈리아 제약회사)와의 상업적 제휴를 통해 라틴아메리카 전역에서 일련의 안과용 의약품에 대한 독점적 라이선스 및 판매권을 획득함으로써 라틴아메리카에서 안과용 의약품 포트폴리오를 확대했습니다.

본 조사의 주요 특징

• 이 보고서는 2024년을 기준 연도로 하여 2025-2032년까지의 예측 기간 동안 세계 바이러스성 결막염 치료제 시장을 상세히 분석하여 시장 규모를 예측하고 있습니다.
• 다양한 부문에 걸친 잠재적 수익 기회를 파악하고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
• 또한 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 지역별 전망, 주요 기업의 경쟁 전략 등에 대한 중요한 인사이트를 제공합니다.
• 이 보고서는 회사 개요, 재무 실적, 제품 포트폴리오, 지리적 입지, 유통 전략, 주요 개발 및 전략, 미래 계획 등의 매개 변수를 기반으로 세계 바이러스성 결막염 치료제 시장의 주요 업체를 프로파일링합니다.
• 이 보고서의 인사이트를 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 기술 개선, 시장 확대, 마케팅 전술에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
• 세계 바이러스성 결막염 치료제 시장 보고서는 투자자, 공급업체, 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 이 산업의 다양한 이해관계자를 대상으로 합니다.
• 이해관계자들은 바이러스성 결막염 치료제 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 용이하게 할 수 있습니다.

목차

제1장 조사 목적과 가정

• 조사 목적
• 가정
• 약어

제2장 시장 전망

• 보고서 설명
  • 시장 정의와 범위
• 주요 요약

제3장 시장 역학, 규제, 동향 분석

• 시장 역학
  • 성장 촉진요인
  • 성장 억제요인
  • 시장 기회
• 영향 분석
• 최근의 테스트 발사
• 역학
• 합병, 인수, 협업
• 규제 시나리오
• PEST 분석

제4장 세계의 바이러스성 결막염 치료제 시장, 약물 종류별, 2020-2032년

• 소개
• 항생제
• 인공눈물
• 충혈 완화제
• 항히스타민제
• NSAIDs
• 항바이러스제
• 기타

제5장 세계의 바이러스성 결막염 치료제 시장, 바이러스 유형별, 2020-2032년

• 소개
• 아데노바이러스
• 엔테로바이러스
• 기타(단순포진바이러스(HSV) 등)

제6장 세계의 바이러스성 결막염 치료제 시장, 유통 채널별, 2020-2032년

• 소개
• 병원 약국
• 소매 약국
• 온라인 약국

제7장 세계의 바이러스성 결막염 치료제 시장, 지역별, 2020-2032년

• 소개
• 북미
  • 미국
  • 캐나다
• 유럽
  • 영국
  • 독일
  • 이탈리아
  • 프랑스
  • 스페인
  • 러시아
  • 기타 유럽
• 아시아태평양
  • 중국
  • 인도
  • 일본
  • ASEAN 국가
  • 호주
  • 한국
  • 기타 아시아태평양
• 라틴아메리카
  • 브라질
  • 멕시코
  • 아르헨티나
  • 기타 라틴아메리카
• 중동
  • GCC 국가
  • 이스라엘
  • 기타 중동
• 아프리카
  • 북아프리카
  • 중앙아프리카
  • 남아프리카공화국

제8장 경쟁 구도

• 기업 개요
  • AbbVie Inc.
  • Takeda Pharmaceutical Company Limited
  • Bausch Health Companies Inc.
  • Panoptes Pharma Ges.mbH
  • NovaBay Pharmaceuticals, Inc.
  • Nicox, NanoViricides Inc.
  • Novartis International AG
  • Pfizer Inc.
  • Johnson & Johnson
  • GlaxoSmithKline Plc.
  • Santen Pharmaceutical Co.Ltd.
  • Alcon
  • Okogen Inc.

제9장 섹션

• 참고문헌
• 조사 방법

영문목차

Viral Conjunctivitis Drugs Market is estimated to be valued at USD 375 Mn in 2025 and is expected to reach USD 531.2 Mn by 2032, growing at a compound annual growth rate (CAGR) of 5.1% from 2025 to 2032.

Viral conjunctivitis is an acute conjunctival infection that is caused due to various viruses such adenovirus, herpes simplex virus etc. Viral conjunctivitis is responsible for majority of infectious conjunctivitis accounting for up to 75% of cases. Characteristics of occular viral conjunctivitis include redness, blood vessel engorgement, ocular discharge, pain, photophobia etc. Viral conjunctivitis that is caused by a group of adenoviruses is called Epidemic Keratoconjunctivitis (EKC). This family of adenoviruses contains different serotypes that can cause pharyngoconjunctival fever and nonspecific follicular conjunctivitis as well. According to the article published in the American Academy of Ophthalmology: 2018, adenoviral conjunctivitis is the most common type of eye infection in adult population. The adenoviral conjunctivitis is highly contagious as the virus causing the infection can survive on a countertop or a similar surface for several weeks.

Market Dynamics

Market players are conducting clinical trials for developing more efficient treatments for adenoviral conjunctivitis, which could contribute to the growth of the market over the forecast period. For instance, in 2017, Shire Plc, subsidiary of Takeda Pharmaceutical Company, initiated clinical trials for testing the safety and efficacy of its drug candidate SHP640 for the treatment of adults and children suffering from adenoviral conjunctivitis.

Market players are focusing on the launch of new products, which is expected to strengthen their position in the global market. For instance, in 2018, Allergan plc., a subsidiary of Abbvie Inc., launched a new over-the-counter (OTC) artificial tear formulation, REFRESH REPAIR Lubricant Eye Drops. It is formulated with carboxymethylcellulose (CMC), hyaluronic acid (HA, an inactive ingredient), and osmoprotectants that protects the eyes from the harmful effects of conjunctivitis symptoms like dry eyes.

Market players are involved in expanding their global presence by entering into partnerships with other companies in order to enhance distribution, this is expected to drive the growth of the viral conjunctivitis drugs market. For instance, in 2018, Mundipharma Deutschland GmbH & Co. KG, a pharmaceutical company, expanded its ophthalmology portfolio in Latin America by entering into a commercial partnership with NTC - an Italian pharmaceutical company, for obtaining exclusive rights to license and distribute a range of ophthalmic medicines across the Latin America region.

Key features of the study

• This report provides an in-depth analysis of global viral conjunctivitis drugs market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period 2025-2032, considering 2024 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players.
• It profiles leading players in the global viral conjunctivitis drugs market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans.
• Key companies covered as a part of this study include AbbVie Inc., Takeda Pharmaceutical Company Limited, Bausch Health Companies Inc., Panoptes Pharma Ges.m.b.H, NovaBay Pharmaceuticals, Inc., Nicox, NanoViricides Inc., Novartis International AG, Pfizer Inc., Johnson & Johnson, GlaxoSmithKline Plc., and Okogen Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics.
• The global viral conjunctivitis drugs market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision making through various strategy matrices used in analyzing the viral conjunctivitis drugs market.

Market Segmentation

• Global Viral Conjunctivitis Drugs Market, By Drug Class
  • Artificial tears
  • Decongestants
  • Anti-histamines
  • NSAIDS
  • Anti-Viral drugs
  • Steroids
  • Antibiotics
• Global Viral Conjunctivitis Drugs Market, By Virus Type
  • Adenovirus
  • Enterovirus
  • Others
• Global Viral Conjunctivitis Drugs Market, By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Viral Conjunctivitis Drugs Market, By Region
  • North America
  • By Drug Class
  • Artificial tears
  • Decongestants
  • Anti-histamines
  • NSAIDS
  • Anti-Viral drugs
  • Steroids
  • Antibiotics
  • By Virus Type
  • Adenovirus
  • Enterovirus
  • Others
  • By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Country
  • U.S.
  • Canada
  • Latin America
  • By Drug Class
  • Artificial tears
  • Decongestants
  • Anti-histamines
  • NSAIDS
  • Anti-Viral drugs
  • Steroids
  • Antibiotics
  • By Virus Type
  • Adenovirus
  • Enterovirus
  • Others
  • By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Country
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
  • By Drug Class
  • Artificial tears
  • Decongestants
  • Anti-histamines
  • NSAIDS
  • Anti-Viral drugs
  • Steroids
  • Antibiotics
  • By Virus Type
  • Adenovirus
  • Enterovirus
  • Others
  • By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Country
  • U.K.
  • Germany
  • Italy
  • Spain
  • France
  • Russia
  • Rest of Europe
  • Asia Pacific
  • By Drug Class
  • Artificial tears
  • Decongestants
  • Anti-histamines
  • NSAIDS
  • Anti-Viral drugs
  • Steroids
  • Antibiotics
  • By Virus Type
  • Adenovirus
  • Enterovirus
  • Others
  • By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Country
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Middle East
  • By Drug Class
  • Artificial tears
  • Decongestants
  • Anti-histamines
  • NSAIDS
  • Anti-Viral drugs
  • Steroids
  • Antibiotics
  • By Virus Type
  • Adenovirus
  • Enterovirus
  • Others
  • By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Country
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • By Drug Class
  • Artificial tears
  • Decongestants
  • Anti-histamines
  • NSAIDS
  • Anti-Viral drugs
  • Steroids
  • Antibiotics
  • By Virus Type
  • Adenovirus
  • Enterovirus
  • Others
  • By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Country/Region
  • South Africa
  • Central Africa
  • North Africa
• Company Profiles
  • AbbVie Inc.
  • Takeda Pharmaceutical Company Limited
  • Bausch Health Companies Inc.
  • Panoptes Pharma Ges.m.b.H
  • NovaBay Pharmaceuticals, Inc.
  • Nicox
  • NanoViricides Inc.
  • Novartis International AG
  • Pfizer Inc.
  • Johnson & Johnson
  • GlaxoSmithKline Plc.
  • Okogen Inc.

Table of Contents

1. Research Objective and Assumption

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Drug Class
  • Market Snippet, By Virus Type
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Recent Test Launches
• Epidemiology
• Merger, Acquisition, and Collaborations
• Regulatory Scenario
• Key Developments
• PEST Analysis

4. Global Viral Conjunctivitis Drugs Market, By Drug Class, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021-2032
  • Segment Trends
• Antibiotics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Segment Trends
• Artificial tears
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Segment Trends
• Decongestants
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Segment Trends
• Anti-histamines
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Segment Trends
• NSAIDS
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Segment Trends
• Anti-Viral drugs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Segment Trends
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020 -2032, (USD Mn)
  • Segment Trends

5. Global Viral Conjunctivitis Drugs Market, By Virus Type, 2020 - 2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021-2032
  • Segment Trends
• Adenovirus
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD Mn)
  • Segment Trends
• Enterovirus
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD Mn)
  • Segment Trends
• Others (Herpes Simplex Virus (HSV), etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD Mn)
  • Segment Trends

6. Global Viral Conjunctivitis Drugs Market, By Distribution Channel, 2020 - 2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021-2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

7. Global Viral Conjunctivitis Drugs Market, By Region, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021-2032
  • Segment Trends
• North America
  • Introduction
  • Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2020-2032, (USD Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Virus Type, 2020-2032, (USD Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2020-2032, (USD Mn)
  • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2020-2032, (USD Mn)
    • U.S.
    • Canada
• Europe
  • Introduction
  • Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2020-2032, (USD Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Virus Type, 2020-2032, (USD Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2020-2032, (USD Mn)
  • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2020-2032, (USD Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2020-2032, (USD Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Virus Type, 2020-2032, (USD Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2020-2032, (USD Mn)
  • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2020-2032, (USD Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Latin America
  • Introduction
  • Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2020-2032, (USD Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Virus Type, 2020-2032, (USD Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2020-2032, (USD Mn)
  • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2020-2032, (USD Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Middle East
  • Introduction
  • Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2020 -2032, (USD Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Virus Type, 2020-2032, (USD Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2020-2032, (USD Mn)
  • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2020-2032, (USD Mn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2020-2032, (USD Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Virus Type, 2020-2032, (USD Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2020-2032, (USD Mn)
  • Market Size and Forecast, By Country, Y-o-Y Growth and By Country/ Region, 2020-2032, (USD Mn)
    • North Africa
    • Central Africa
    • South Africa

8. Competitive Landscape

• Company Profiles
  • AbbVie Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Takeda Pharmaceutical Company Limited
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Bausch Health Companies Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Panoptes Pharma Ges.m.b.H
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • NovaBay Pharmaceuticals, Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Nicox, NanoViricides Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Novartis International AG
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Pfizer Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Johnson & Johnson
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • GlaxoSmithKline Plc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Santen Pharmaceutical Co.Ltd.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Alcon
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Okogen Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies

9. Section

• References
• Research Methodology
• About us and Sales Contact